Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H12Cl2N4 |
Molecular Weight | 343.21 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C4=CC(Cl)=CC=C4N12
InChI
InChIKey=JOFWLTCLBGQGBO-UHFFFAOYSA-N
InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3
Molecular Formula | C17H12Cl2N4 |
Molecular Weight | 343.21 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00897Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017892s038lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00897
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017892s038lbl.pdf
Triazolam is a short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Triazolam has a shorter half-life than chlordiazepoxide, flurazepam, and prazepam and does not generate active metabolites. Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Triazolam is used for the short-term treatment of insomnia. Triazolam`s original brand name is Halcion. Triazolam is withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
0.8 nM [Ki] | |||
Target ID: CHEMBL2094130 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10633039 |
0.59 nM [Ki] | ||
Target ID: CHEMBL2094121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10633039 |
0.8 nM [Ki] | ||
Target ID: CHEMBL2094120 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10633039 |
1.43 nM [Ki] | ||
Target ID: CHEMBL2094122 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10633039 |
1.54 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Halcion Approved UseHalcion is indicated for the short-term treatment of insomnia (generally 7–10 days). Use for more than 2–3 weeks requires complete reevaluation of the patient Launch Date1982 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.39 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8275618/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8275618/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAZOLAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.69 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11503006/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.91 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11503006/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
.ALPHA.-HYDROXYTRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.05 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11503006/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
.ALPHA.-HYDROXYTRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.69 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11503006/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.78 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8275618/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
13.05 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8275618/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAZOLAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.93 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11503006/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.88 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11503006/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
.ALPHA.-HYDROXYTRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.99 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11503006/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
.ALPHA.-HYDROXYTRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11503006/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.27 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8275618/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.07 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8275618/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAZOLAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11503006/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.54 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11503006/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
.ALPHA.-HYDROXYTRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.49 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11503006/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
.ALPHA.-HYDROXYTRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11503006/ |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAZOLAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3 mg single, oral Highest studied dose |
unhealthy, 21 - 60 years Health Status: unhealthy Age Group: 21 - 60 years Sex: M Sources: |
Disc. AE: Ataxia, Drowsiness... AEs leading to discontinuation/dose reduction: Ataxia (1 patient) Sources: Drowsiness (1 patient) |
0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Coordination abnormal, Drowsiness... AEs leading to discontinuation/dose reduction: Coordination abnormal Sources: Drowsiness Groggy Somnolence Depression Restlessness Dizziness Lightheadedness Headache Nausea Visual disturbance Nervousness Abdominal distress Bladder disorders NEC Aching in limb Backache Blepharitis |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ataxia | 1 patient Disc. AE |
3 mg single, oral Highest studied dose |
unhealthy, 21 - 60 years Health Status: unhealthy Age Group: 21 - 60 years Sex: M Sources: |
Drowsiness | 1 patient Disc. AE |
3 mg single, oral Highest studied dose |
unhealthy, 21 - 60 years Health Status: unhealthy Age Group: 21 - 60 years Sex: M Sources: |
Abdominal distress | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Aching in limb | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Backache | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Bladder disorders NEC | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Blepharitis | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Coordination abnormal | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Depression | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Dizziness | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Drowsiness | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Groggy | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Headache | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Lightheadedness | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Nausea | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Nervousness | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Restlessness | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Somnolence | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Visual disturbance | Disc. AE | 0.25 mg 1 times / day steady, oral Recommended Dose: 0.25 mg, 1 times / day Route: oral Route: steady Dose: 0.25 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
yes | ||||
Page: 7.0 |
yes | yes (co-administration study) Comment: contraindicated with strong CYP3A inhibitors such as ketoconazole, itraconazole, nefazodone, ritonavir, indinavir, nelfinavir, saquinavir, and lopinavir; from 2019 label: grapefruit juice increased maximum plasma concentration of triazolam by 25% and increased AUC by 48% Page: 7.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. | 2001 |
|
Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. | 2001 |
|
Brain glycine levels in triazolam-treated albino rats. | 2001 |
|
Central serotonergic mechanisms on head twitch response induced by benzodiazepine receptor agonists. | 2001 |
|
Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. | 2001 Aug |
|
Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people. | 2001 Aug |
|
Determination of triazolam involving its hydroxy metabolites in hair shaft and hair root by reversed-phase liquid chromatography with electrospray ionization mass spectrometry and application to human hair analysis. | 2001 Aug 15 |
|
Pregabalin enhances nonrapid eye movement sleep. | 2001 Dec |
|
Triazolam discrimination in squirrel monkeys distinguishes high-efficacy agonists from other benzodiazepines and non-benzodiazepine drugs. | 2001 Feb |
|
Sensitive gas chromatographic--mass spectrometric screening of acetylated benzodiazepines. | 2001 Feb 23 |
|
The hypnotic effect of propofol in the medial preoptic area of the rat. | 2001 Jul 6 |
|
Benzodiazepines as a social problem: the case of halcion. | 2001 Jul-Aug |
|
A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. | 2001 Jun |
|
CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit. | 2001 May |
|
Triazolam impairs inhibitory control of behavior in humans. | 2001 Nov |
|
Retrograde facilitation of memory by triazolam: effects on automatic processes. | 2001 Nov |
|
Pain experience during transvaginal aspiration of immature oocytes. | 2001 Nov |
|
The hypnotic actions of the fatty acid amide, oleamide. | 2001 Nov |
|
Effects of triazolam on brain activity during episodic memory encoding: a PET study. | 2001 Nov |
|
Potency of positive gamma-aminobutyric acid(A) modulators to substitute for a midazolam discriminative stimulus in untreated monkeys does not predict potency to attenuate a flumazenil discriminative stimulus in diazepam-treated monkeys. | 2001 Sep |
|
Tolerability of hypnosedatives in older patients. | 2002 |
|
Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. | 2002 |
|
Sensitive method for the detection of 22 benzodiazepines by gas chromatography-ion trap tandem mass spectrometry. | 2002 Apr 19 |
|
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. | 2002 Aug |
|
Effect of zaleplon on learning and memory in rats. | 2002 Aug |
|
Discriminative-stimulus effects of modafinil in cocaine-trained humans. | 2002 Aug 1 |
|
Alcohol and triazolam: differential effects on memory, psychomotor performance and subjective ratings of effects. | 2002 Dec |
|
A role for cryptochromes in sleep regulation. | 2002 Dec 20 |
|
[Identification of estazolam, alprazolam and triazolam in human urine by LC/MSn]. | 2002 Feb |
|
[Pharmacological profile and clinical effect of zolpidem (Myslee tablets), a hypnotic agent]. | 2002 Feb |
|
Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic. | 2002 Jan 2 |
|
The study of polysomnography and sleepiness the morning after administration of triazolam and brotizolam. | 2002 Jun |
|
Feeding melatonin enhances the phase shifting response to triazolam in both young and old golden hamsters. | 2002 May |
|
Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. | 2002 May |
|
Effects of triazolam, 8-OH-DPAT, and buspirone on repeated acquisition in squirrel monkeys. | 2002 Nov |
|
Acute and chronic effects of the neuroactive steroid pregnanolone on schedule-controlled responding in rhesus monkeys. | 2002 Nov |
|
Interactions between recreational drugs and antiretroviral agents. | 2002 Oct |
|
Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. | 2002 Sep 13 |
|
Melatonin microinjection into the medial preoptic area increases sleep in the rat. | 2002 Sep 13 |
|
Pharmacokinetic interactions with rifampicin : clinical relevance. | 2003 |
|
[Cytochrome P450 3A4 and Benzodiazepines]. | 2003 |
|
Lopinavir/ritonavir: a review of its use in the management of HIV infection. | 2003 |
|
Clinical pharmacokinetic profile of modafinil. | 2003 |
|
[Diagnostics and treatment of sleep disorders in elderly people]. | 2003 Apr-Jun |
|
Long-, intermediate- and short-acting benzodiazepine effects on human sleep EEG spectra. | 2003 Feb |
|
Semi-micro column HPLC of triazolam in rat plasma and brain microdialysate and its application to drug interaction study with itraconazole. | 2003 Jan 15 |
|
Effects of short-acting hypnotics on sleep latency in rats placed on grid suspended over water. | 2003 Jan 24 |
|
Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. | 2003 Jun |
|
Anxiolysis in general dental practice. | 2003 Mar |
|
Cocaine-like subjective effects of nicotine are not blocked by the D1 selective antagonist ecopipam (SCH 39166). | 2003 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/halcion.html
The recommended dose for most adults is 0.25 mg before retiring. A dose of 0.125 mg may be found to be sufficient for some patients (e.g., low body weight). A dose of 0.5 mg should be used only for exceptional patients who do not respond adequately to a trial of a lower dose since the risk of several adverse reactions increases with the size of the dose administered. A dose of 0.5 mg should not be exceeded.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9536021
Triazolam inhibited [3H]flunitrazepam binding with an IC50 value of 0.85 nM and a Ki value of 0.50 nM in mice.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:55:44 GMT 2025
by
admin
on
Mon Mar 31 17:55:44 GMT 2025
|
Record UNII |
1HM943223R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN05CD05
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
||
|
NDF-RT |
N0000007542
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
||
|
NDF-RT |
N0000175694
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
||
|
LIVERTOX |
NBK547843
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
||
|
DEA NO. |
2887
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
||
|
WHO-ATC |
N05CD05
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1HM943223R
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
6759
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
2729
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
DB00897
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
DTXSID6046763
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
m11035
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000092518
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
249-307-3
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
TRIAZOLAM
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
CHEMBL646
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
5556
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
28911-01-5
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
3409
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
D014229
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
10767
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | RxNorm | ||
|
7313
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
Triazolam
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
1680506
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
C29520
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
9674
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
SUB11258MIG
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY | |||
|
1HM943223R
Created by
admin on Mon Mar 31 17:55:44 GMT 2025 , Edited by admin on Mon Mar 31 17:55:44 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||